(Q45997043)

English

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

1 reference

based on heuristic

inferred from title

mipomersen parent acid

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Rosie Z Yu

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Richard S Geary

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Joann D Flaim

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Gina C Riley

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Diane L Tribble

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

André A vanVliet

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Mark K Wedel

7

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

publication date

1 January 2009

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

48

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

39-50

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

https://scigraph.springernature.com/pub.10.2165/0003088-200948010-00003

0 references

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioanalytical method validation--a revisit with a decade of progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/19071883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/0003088-200948010-00003

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19071883

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45997043&oldid=2143323771"